{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:45:49Z","timestamp":1792111549173,"version":"4.4.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Rezolute, Inc."},{"DOI":"10.13039\/100007877","name":"Joslin Diabetes Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory hypoglycemia is common in malignant insulin-secreting tumors and is associated with substantial morbidity. Ersodetug is a fully human monoclonal antibody that allosterically attenuates insulin receptor signaling with the potential to treat various forms of hyperinsulinism (HI). We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ersodetug was administered intravenously at 6 or 9 mg\/kg every 1-2 weeks initially, followed by a frequency of every 2-5 weeks, as appropriate. Glycemic, functional, and safety outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight adults (4M\/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1). No drug-related serious adverse events were observed. Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (&amp;lt;70 mg\/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, \u22128.2 to \u22121.1]; P = .02). These glycemic improvements permitted hospital discharge and reductions in other antihypoglycemic therapies beyond glucose infusion rate (pseudo-median change, \u22122.5; 90% CI, \u22123.5 to \u22121.0; P = .02), with associated improvements in ECOG status. The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag318","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:53:47Z","timestamp":1785930827000},"page":"e2382-e2391","source":"Crossref","is-referenced-by-count":0,"title":["Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors"],"prefix":"10.1210","volume":"111","author":[{"given":"Jonathan","family":"Strosberg","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center , Tampa, FL 33612 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M","family":"Brown","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center (Harvard Medical School) , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Stanford University Medical Center , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Stanford University Medical Center , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo Arturo","family":"Nore\u00f1a","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Stanford University Medical Center , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen I","family":"Yerevanian","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Massachusetts General Hospital (Harvard Medical School) , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lester","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-2628","authenticated-orcid":false,"given":"Ole-Petter R","family":"Hamnvik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Brigham and Women's Hospital (Harvard Medical School) , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center , 3000 CA Rotterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine K","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Rezolute Inc. , Redwood City, CA 94065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Saha","sequence":"additional","affiliation":[{"name":"Rezolute Inc. , Redwood City, CA 94065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3173-7368","authenticated-orcid":false,"given":"Davelyn E","family":"Hood","sequence":"additional","affiliation":[{"name":"Rezolute Inc. , Redwood City, CA 94065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Roberts","sequence":"additional","affiliation":[{"name":"Rezolute Inc. , Redwood City, CA 94065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-3991","authenticated-orcid":false,"given":"Jonathan M","family":"Dreyfuss","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center (Harvard Medical School) , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-3429","authenticated-orcid":false,"given":"Mary-Elizabeth","family":"Patti","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center (Harvard Medical School) , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"4","key":"2026101520051069000_dgag318-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/clinem\/dgad641","article-title":"Approach to the patient: insulinoma","volume":"109","author":"Hofland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101520051069000_dgag318-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100305","article-title":"Paraneoplastic hypoglycemia: an overview for optimal clinical guidance","volume":"23","author":"Karamanolis","year":"2024","journal-title":"Metabol Open"},{"issue":"6","key":"2026101520051069000_dgag318-B3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","author":"Okabayashi","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2026101520051069000_dgag318-B4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","article-title":"Functioning insulinoma\u2013incidence, recurrence, and long-term survival of patients: a 60-year study","volume":"66","author":"Service","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2026101520051069000_dgag318-B5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/am.am_67_22","article-title":"Non-islet cell tumor-related hypoglycemia in a case of metastatic gastrointestinal stromal tumor: a rare paraneoplastic syndrome: a case report","volume":"19","author":"Ghosh","year":"2022","journal-title":"Apollo Med"},{"issue":"4","key":"2026101520051069000_dgag318-B6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1210\/jc.2008-2031","article-title":"Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007","volume":"94","author":"Placzkowski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101520051069000_dgag318-B7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.suc.2009.06.009","article-title":"Insulinoma","volume":"89","author":"Mathur","year":"2009","journal-title":"Surg Clin North Am"},{"issue":"8","key":"2026101520051069000_dgag318-B8","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026101520051069000_dgag318-B9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2016.00029","article-title":"Hyperinsulinemic hypoglycemia\u2014the molecular mechanisms","volume":"7","author":"Nessa","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026101520051069000_dgag318-B10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrm3351","article-title":"Regulation of glucose transport by insulin: traffic control of GLUT4","volume":"13","author":"Leto","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"2026101520051069000_dgag318-B11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1210\/jc.2017-00822","article-title":"Attenuation of insulin action by an allosteric insulin receptor antibody in healthy volunteers","volume":"102","author":"Johnson","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101520051069000_dgag318-B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100611","article-title":"Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism","volume":"6","author":"Demirbilek","year":"2025","journal-title":"Med"},{"issue":"1","key":"2026101520051069000_dgag318-B13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4161\/mabs.26871","article-title":"Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia","volume":"6","author":"Corbin","year":"2014","journal-title":"MAbs"},{"issue":"8","key":"2026101520051069000_dgag318-B14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMc2307576","article-title":"Anti-insulin receptor antibody for malignant insulinoma and refractory hypoglycemia","volume":"389","author":"Osataphan","year":"2023","journal-title":"N Engl J Med"},{"key":"2026101520051069000_dgag318-B15","unstructured":"Strosberg J, Brown SM, Shaheen S, et al \u00a0Ersodetug series supplementary information. 10.5281\/zenodo.20147071"},{"issue":"3","key":"2026101520051069000_dgag318-B16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pan.2018.01.009","article-title":"Insulinoma: a retrospective study analyzing the differences between benign and malignant tumors","volume":"18","author":"C\u00e2mara-de-Souza","year":"2018","journal-title":"Pancreatology"},{"issue":"4","key":"2026101520051069000_dgag318-B17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-19-0989","article-title":"Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study","volume":"182","author":"Veltroni","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026101520051069000_dgag318-B18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjsurg.2020.08.003","article-title":"Comparison of benign and malignant insulinoma","volume":"221","author":"Sada","year":"2021","journal-title":"Am J Surg"},{"issue":"2","key":"2026101520051069000_dgag318-B19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"5-6","key":"2026101520051069000_dgag318-B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ando.2013.07.001","article-title":"Malignant insulinoma: recommendations for characterisation and treatment","volume":"74","author":"Baudin","year":"2013","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"2026101520051069000_dgag318-B21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ando.2013.05.009","article-title":"Treatment: symptomatic treatment of hypoglycaemia","volume":"74","author":"Tabarin","year":"2013","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"2026101520051069000_dgag318-B22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bpg.2012.12.003","article-title":"Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"2026101520051069000_dgag318-B23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.14310\/horm.2002.1706","article-title":"Glycemic control in patients with insulinoma","volume":"15","author":"Matej","year":"2016","journal-title":"Hormones (Athens)"},{"issue":"5","key":"2026101520051069000_dgag318-B24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","article-title":"Endocrine tumours of the pancreas","volume":"19","author":"Oberg","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"2026101520051069000_dgag318-B25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"issue":"6","key":"2026101520051069000_dgag318-B26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1634\/theoncologist.2010-0222","article-title":"Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues","volume":"16","author":"Fiebrich","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"2026101520051069000_dgag318-B27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/JOE-12-0351","article-title":"mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells","volume":"216","author":"Le Bacquer","year":"2013","journal-title":"J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag318\/70501746\/dgag318.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/e2382\/70501746\/dgag318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/e2382\/70501746\/dgag318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:05:20Z","timestamp":1792109120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/11\/e2382\/8752955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,8,6]]},"published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag318","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,6]]}}}